You are here: Industry Insights > Taletrectinib

News List

Innovent and AnHeart Announce Interim Data from Phase 2 Trial of Taletrectinib in ROS1-Positive NSCLC at the CSCO 2021 Annual Meeting prnasia
September 28, 2021
Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer...
Innovent Announces First Patient Dosed in the Phase II Basket Trial of Taletrectinib for Solid Tumors with NTRK Fusion prnasia
June 21, 2021
Innovent Biologics, Inc. announced that the first patient has been dosed in a Phase II basket trial of taletrectinib for solid tumors containing NTRK fusion (NCT04617054).
From Bayer China to IVF Applications: A Summary of VeChain's Blockchain-based Use Cases in Medical and Healthcare prnasia
June 18, 2021
Innovent Biologics, Inc. announced that the first patient has been dosed in a Phase II basket trial of taletrectinib for solid tumors containing NTRK fusion (NCT04617054).
Innovent Biologics and AnHeart Therapeutics Jointly Announce Exclusive License Agreement for Taletrectinib in Greater China prnasia
June 01, 2021
Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, and AnHeart Therapeutics Co., Ltd. ...